Recent Division Publications

Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?
H. Thomas, D. Hippe, Parisa Forouzannezhad, et al. - Published 2022 - DISCOVER ONCOLOGY

Regularizing the Deepsurv Network Using Projection Loss For Medical Risk Assessment
Phawis Thammasorn, S. K. Schaub, D. Hippe, et al. - Published 2022 - IEEE ACCESS

Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer.
K. Horn, H. Thomas, H. Vesselle, et al. - Published 2021 - CLINICAL NUCLEAR MEDICINE

Performance Characteristics of a Dual-Sided Position-Sensitive Sparse-Sensor Detector for Gamma-ray Imaging
W. Hunter, Donald D. Witt, R. Miyaoka - Published 2021

Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma
K. Labadie, A. Ludwig, A. Lehnert, et al. - Published 2021 - SCIENTIFIC REPORTS

Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer
S. Bowen, D. Hippe, H. Thomas, et al. - Published 2021 - ADVANCES IN RADIATION ONCOLOGY

Prognostic Value and Peripheral Immunologic Correlates of Early FDG PET Response Imaging in a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable NSCLC.
J Zeng, D. Hippe, H. Thomas, et al. - Published 2021 - INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY, BIOLOGY, PHYSICS

Prognostic value and peripheral immunologic correlates of early FDG PET response imaging in a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer
S. Bowen, D. Hippe, H. Thomas, et al. - Published 2021 - MEDRXIV

A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome
B. Sandmaier, D. Wilbur, D. Hamlin, et al. - Published 2021

18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study
Perrin E. Romine, Lanell M Peterson, B. Kurland, et al. - Published 2021 - BREAST CANCER RESEARCH : BCR

Clinical Impact of FDG PET/CT of the Lower Extremities in Patients With Merkel Cell Carcinoma With Primary Disease Site Outside of the Lower Extremities.
M. Ishiyama, F. Behnia, H. Vesselle - Published 2021 - AJR. AMERICAN JOURNAL OF ROENTGENOLOGY

A Path to Qualification of PET/MR Scanners for Multicenter Brain Imaging Studies: Evaluation of MR-based Attenuation Correction Methods Using a Patient Phantom.
C. Catana, R. Laforest, Hongyu An, et al. - Published 2021 - JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE

Adaptive Fluorodeoxyglucose-Positron Emission Tomography Based Chemotherapy Selection for Metastatic Non-small Cell Lung Cancer
K. Eaton, Perrin E. Romine, R. Martins, et al. - Published 2021 - CUREUS

Evaluation of attenuation correction in PET/MRI with synthetic lesion insertion.
M. Hamdi, Y. Natsuaki, K. Wangerin, et al. - Published 2021 - JOURNAL OF MEDICAL IMAGING

Neurolymphomatosis; a case report.
N. Aboueldahab, M. Shafik, A. Megahed, et al. - Published 2021 - CLINICAL IMAGING

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
R. Lynch, R. Cassaday, Stephen D Smith, et al. - Published 2021 - THE LANCET. HAEMATOLOGY